SEC Filings

Form 10-Q
ADURO BIOTECH, INC. filed this Form 10-Q on 10/30/2018
Document Outline
Entire Document (5762.8 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - Table of Contents
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - ADURO BIOTECH, INC.
Page 5 - ADURO BIOTECH, INC.
Page 6 - ADURO BIOTECH, INC.
Page 7 - ADURO BIOTECH, INC.
Page 8 - Collaboration and license revenue
Page 9 - Recently Adopted Accounting Pronouncements
Page 10 - N/A
Page 11 - 3. Fair Value Measurements
Page 12 - N/A
Page 13 - 4. Balance Sheet Components
Page 14 - Accrued Expenses and Other Liabilities
Page 15 - 6. Collaboration Agreements
Page 16 - N/A
Page 17 - Janssen ADU-214 Agreement
Page 18 - Indemnification
Page 19 - 8. Stockholders Equity
Page 20 - Stock Options
Page 21 - 2015 Employee Stock Purchase Plan
Page 22 - 11. Net Loss per Common Share
Page 23 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Page 24 - Components of Operating Results
Page 25 - General and Administrative Expenses
Page 26 - Research and Development Expenses
Page 27 - Comparison of the Nine months ended September 30, 2018 and 2017
Page 28 - General and Administrative Expenses
Page 29 - Cash Flows
Page 30 - Off-Balance Sheet Arrangements
Page 31 - Recently Adopted Pronouncements
Page 32 - PART II OTHER INFORMATION
Page 33 - Risks Related to the Development and Commercialization of Our Current and Future Product Candidates
Page 34 - We may not be successful in our efforts to use and expand our technologies to build a pipeline of pr
Page 35 - Any delay, suspension, termination or request to repeat or redesign a trial could increase our costs
Page 36 - Our product candidates may cause undesirable side effects or may have other properties that could ha
Page 37 - The market opportunities for our product candidates may be limited to those patients who are ineligi
Page 38 - We currently have no marketing and sales organization and have no experience in marketing products.
Page 39 - We face significant competition from other biotechnology and pharmaceutical companies, and our busin
Page 40 - We are highly dependent on our key personnel, and if we are not successful in attracting and retaini
Page 41 - Business disruptions could seriously harm our future revenue and financial condition and increase ou
Page 42 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 43 - We rely and will rely on third parties to conduct our clinical trials. If these third parties do not
Page 44 - We are subject to a multitude of manufacturing risks, any of which could substantially increase our
Page 45 - Risks Related to Government Regulation
Page 46 - Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not
Page 47 - Coverage and reimbursement may be limited or unavailable in certain market segments for our product
Page 48 - Our product candidates may be subject to government price controls that may affect our revenue.
Page 49 - N/A
Page 50 - Our current and future relationships with customers and third-party payors in the United States and
Page 51 - If we or our third-party manufacturers use hazardous and biological materials in a manner that cause
Page 52 - Risks Related to Our Intellectual Property
Page 53 - Listeria
Page 54 - Some jurisdictions may require us to grant licenses to third parties. Such compulsory licenses could
Page 55 - Changes in patent law could increase the uncertainties and costs surrounding the prosecution of our
Page 56 - We may become involved in lawsuits to protect or enforce our intellectual property, which could be e
Page 57 - If we are unable to protect the confidentiality of our proprietary information and know-how, the val
Page 58 - The recently passed comprehensive tax reform bill could materially and adversely affect our business
Page 59 - Risks Related to Ownership of Our Common Stock
Page 60 - Once we are no longer an emerging growth company we will be subject to additional laws and regulatio
Page 61 - Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a chang
Page 62 - Revenue from Contracts with Customers
Page 63 - EXHIBIT INDEX
Page 64 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer